<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput xmlns:ns2="local" id="264134"><TitleDisplay>Pharmacological Activation of Brown Adipose Tissue Metabolism</TitleDisplay><TitleOfficial>Pharmacological or Cold-induced Activation of Brown Adipose Tissue Metabolism</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02811289</Identifier><Identifier type="Organisational Study">2016-1086</Identifier><Identifier type="Other">GB6</Identifier></Identifiers><Indications><Indication id="837">Non-insulin dependent diabetes</Indication></Indications><BiomarkerNames><BiomarkerName id="425" role="Therapeutic effect marker" type="Proteomic">C-peptide</BiomarkerName><BiomarkerName id="808" role="Therapeutic effect marker" type="Biochemical;Genomic;Proteomic">Insulin</BiomarkerName><BiomarkerName id="2265" role="Therapeutic effect marker" type="Physiological">Maximal oxygen uptake</BiomarkerName><BiomarkerName id="10170" role="Therapeutic effect marker" type="Physiological">Carbon dioxide output</BiomarkerName><BiomarkerName id="28655" role="Therapeutic effect marker" type="Structural (imaging)">Brown adipose tissue</BiomarkerName><BiomarkerName id="28800" role="Therapeutic effect marker" type="Cellular">Pancreatic beta cells</BiomarkerName><BiomarkerName id="45827" role="Therapeutic effect marker" type="Physiological">Homeostasis model assessment insulin sensitivity</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>dynamic PET/CT scanning</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>(3-3H)-glucose</Name></Intervention><Intervention type="InterventionPrimary"><Name>(U-13C)-palmitate</Name></Intervention><Intervention type="InterventionPrimary"><Name>11C-acetate</Name></Intervention><Intervention type="InterventionPrimary"><Name>18-fluorodeoxyglucose</Name></Intervention><Intervention type="InterventionPrimary"><Name>2H-glycerol</Name></Intervention><Intervention type="InterventionPrimary"><Name>mirabegron</Name><Drug id="39730">mirabegron</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>cold exposure</Name></Intervention></Interventions></InterventionsControlByRegimen><InterventionsControlByRegimen regimenType="combo"><Interventions><Intervention type="InterventionControl"><Name>(3-3H)-glucose</Name></Intervention><Intervention type="InterventionControl"><Name>(U-13C)-palmitate</Name></Intervention><Intervention type="InterventionControl"><Name>11C-acetate</Name></Intervention><Intervention type="InterventionControl"><Name>18-fluorodeoxyglucose</Name></Intervention><Intervention type="InterventionControl"><Name>2H-glycerol</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="39730">mirabegron</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="23853">Universite de Sherbrooke</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="39730" type="Drug"><TargetEntity id="277326" type="siDrug">Mirabegron</TargetEntity></SourceEntity><SourceEntity id="23853" type="Company"><TargetEntity id="4297631436" type="organizationId">Universite De Sherbrooke</TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="42" type="Action"><TargetEntity id="61" type="Mechanism">beta3-Adrenoceptor Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="23853">Universite de Sherbrooke</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="42">Beta 3 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology id="641">Controlled release formulation</Technology><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>22</PatientCountEnrollment><DateStart>2016-08-05T00:00:00Z</DateStart><DateEnd type="actual">2018-07-05T00:00:00Z</DateEnd><DateChangeLast>2018-10-12T16:16:35Z</DateChangeLast><DateAdded>2016-07-08T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Universite de Sherbrooke</Affiliation><Name>Andre Carpentier</Name></Contact><Contact type="Scientific contact"><Affiliation>Centre de recherche du CHUS</Affiliation><Name>André Carpentier, M.D.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;BMI&amp;lt; 30 kg/m2&lt;/li&gt;&lt;li&gt;Normal glucose tolerance (2 h post 75 g OGTT glucose at&amp;lt; 7.8 mmol/l)&lt;/li&gt;&lt;li&gt;HbA1c&amp;lt; 5.8%&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Overt cardiovascular disease as assessed by medical history, physical exam, and abnormal ECG&lt;/li&gt;&lt;li&gt;Treatment with any drug known to affect lipid or carbohydrate metabolism&lt;/li&gt;&lt;li&gt;Presence of liver or renal disease, uncontrolled thyroid disorder, previous pancreatitis, bleeding disorder, or other major illness&lt;/li&gt;&lt;li&gt;Smoking (&amp;gt; 1 cigarette/day) and/or consumption of &amp;gt; 2 alcoholic beverages/day&lt;/li&gt;&lt;li&gt;Prior history or current fasting plasma cholesterol level&amp;gt; 7 mmol/l or fasting TG &amp;gt; 6 mmol/l&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>BAT net glucose uptake: will be assessed using intravenous injection of 18FDG with sequential dynamic PET/CT scanning</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>BAT oxidative metabolism: will be determined using intravenous injection of 11C-acetate during dynamic PET/CT scanning</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>BAT volume of metabolic activity: will be determined using a total body CT (16 mA) followed by a PET acquisition</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>Whole body organ glucose partitioning: will be determined using a total body CT (16 mA) followed by a PET acquisition be determined using a total body CT (16 mA) followed by a PET acquisition</Description><Timeframe>Two years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Electrocardiogram</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>Energy expenditure: will be determined by indirect calorimetry from VO2 and VCO2 (Vmax29n, Sensormedics)</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>Glucose appearance rate: will be determined using (3-3H)-glucose</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>Insulin secretion rate: will be assessed using deconvolution of plasma C-peptide with standard C-peptide kinetic parameters</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>Insulin sensitivity: will be determined using the HOMA-IR (based on fasting insulin and glucose levels)</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>Lipolysis rate: will be measured using intravenous administration of (13C)-palmitate and (2H)-glycerol, using steele's non steady state equations</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>Metabolite responses: will be determined using a multiplex assay system</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>Beta-cell function: will be assessed by calculation of the disposition index (DI) that is insulin secretion in response to the ambient insulin sensitivity</Description><Timeframe>Two years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to directly compare brown adipose tissue (BAT)      oxidative metabolism under cold versus beta-3-adrenergic agonist stimulation in lean healthy      individuals. The investigator hypothesizes that the acute po administration of a lower      dose of &lt;ulink linkType="Drug" linkID="39730"&gt;mirabegron&lt;/ulink&gt; (50 mg) would result in an increase in BAT oxidative metabolism and      whole-body energy expenditure, to a similar extent as cold exposure, without influencing the      cardiovascular responses previously seen with the higher dose (200 mg).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The first step of the study would be direct comparison of mirabegron (protocol A) versus      cold-induced (protocol B) BAT metabolic activation using 11C-acetate to measure BAT      metabolic activity. The principle of this method would be measurement of tissue fast disappearance      of 11C, a marker of tissue 11CO2 production. This fast tissue 11C clearance thus would give an      index of tissue oxidative metabolism.&lt;br/&gt;A total of ten healthy, non obese men would undergo two identical      5 h procedures in which BAT metabolism would be stimulated with a beta-3-agonist (mirabegron 50 mg)      or using cold exposure, in random order. The investigator would receive approval from Health      Canada to use mirabegron as part of these metabolic investigations. In brief, baseline blood      samples and indirect calorimetry would be performed between time -60 to -30 min followed by      intravenous injection of 11C-acetate with 30 min dynamic PET/CT scanning at room temperature in      both protocol A and B. Mirabegron would be administered orally at time 0 in protocol A      whereas acute cold exposure protocol using a water-conditioned cooling suit would be applied      from time 120 to 300 min in protocol B. At time 210 min (ie, Tmax of plasma mirabegron      level or 90 min after the onset of cold exposure), intravenous injection of 11C-acetate will be      repeated followed by 30 min dynamic PET/CT scanning. Intravenous injection of 18-fluorodeoxyglucose      (18FDG) would be performed at time 270 min, followed by 30 min dynamic PET/CT scanning to      determine BAT net glucose uptake and a whole-body PET/CT scan to determine BAT volume of      metabolic activity and organ-specific glucose partitioning. Patients would also receive iv administration of (3-3H)-glucose (1.5 microCi/min), (U-13C)-palmitate (0.08 micromol/kg/min) and 2H-glycerol (0.05 micromol/kg/min).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>centre de recherche du CHUS</Name><Address1>Sherbrooke</Address1><Address2>Quebec</Address2><Address3>J1H 5N4</Address3><CountrySubDivision>Quebec</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Non-insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="102">Subjects with Good Glycemic Control</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="116">Others</PatientSegment><SubSegments><SubSegment id="117">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02811289</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1501"><Endpoint>Obesity, Body Weight &amp; Fat Tissue Assessment</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1650"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="2457">Lipid oxidation</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="45401"><Endpoint>Imaging/Radiological Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="45429"><Endpoint>Assessment of Metabolic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1370"><Endpoint>Assessment of C-peptide Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1389"><Endpoint>Assessment of Beta Cell Function</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1392">Disposition index (DI)</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1399">Insulin secretion rate</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1412"><Endpoint>Assessment of Insulin Sensitivity</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1416">Homeostasis model assessment (HOMA)- insulin sensitivity index (HOMA-I, HOMA-IR)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1650"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="2458">Lipolysis</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="45401"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1545">Assessment by echocardiography</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="45429"><Endpoint>Assessment of Metabolic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="2449">Energy expenditure and substrate metabolism</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="608"><Criterion>Obese Subjects</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="609">Overweight subjects (Grade 1 obesity, BMI= 25 to 29.9)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="33510"><Criterion>Subjects with specific level of glycemic control</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="606">Subjects with Good Glycemic Control</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="34698"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="692">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="837"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="891"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="911"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="928"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="936">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="932"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="995"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="998">Any change in lipid lowering treatment</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="1072">Significant illness which requires medical attention</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5070"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="881">Subjects co-morbid with hypercholesterolemia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5078"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="5080">Abnormal lab test</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="25123"><Criterion>Subjects with specific cigarette smoking activity</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1073">Smokers</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="29284"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1003">Subjects with history of drug/substance abuse</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2018-05-24T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-06-14T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-07-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-06-03T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-08-23T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput>